Atlas Trials

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Clinical trial NCT06509009 · RECRUITING

Trial details

NCT number
NCT06509009
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma by AJCC V8 Stage
Start date
2024-08-30
Primary completion
2026-05-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.